Should I buy or sell ATRS? ATRS stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Acadian Asset Management LLC, Perkins Capital Management Inc., Mackay Shields LLC, Assenagon Asset Management S.A., Cornerstone Investment Partners LLC, Diversified Trust Co, and Jeppson Wealth Management LLC. All times are ET. Do the numbers hold clues to what lies ahead for the stock? Analysts tracking ATRS have forecast the quarterly EPS to grow by $0.03 per share this quarter, while the same analysts predict the annual EPS to hit $0.06 for the year 2020 and up to $0.25 for 2021. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. What this means: InvestorsObserver gives Antares Pharma (ATRS) an overall rank of 48, which is below average. Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021. Antares Pharma has received 55.85% “outperform” votes from our community. Antares Pharma stock price ended on $3.99 on Thursday after gaining 2.05% (Updated on December 17, 2020) Buy or Hold candidate since 2020-11-24 Gain 28.71% PDF. Learn everything you need to know about successful options trading with this three-part video course. CNN Sans™ & © 2016 Cable News Network. The high price target for ATRS is $7.00 and the low price target for ATRS is $4.50. View all of ATRS's competitors. Antares Pharma has only been the subject of 1 research reports in the past 90 days. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. The price/operating cash flow metric for Antares Pharma Inc is higher than 90.4% of stocks in our set with a positive cash flow. See Antares Pharma, Inc. (ATRS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Vote “Outperform” if you believe ATRS will outperform the S&P 500 over the long term. During the day the stock fluctuated 10.26% from a day low at $3.46 to a day high of $3.82. View real-time stock prices and stock quotes for a full financial overview. Antares Pharma's management team includes the following people: Exec. Learn more. Antares Pharma stock tanked -4.57% to close at $3.13 on the stock market yesterday. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]. Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Do Not Sell My Information. ATRS | Complete Antares Pharma Inc. stock news by MarketWatch. Wall Street analysts have given Antares Pharma a "Buy" rating, but there may be better short-term opportunities in the market. One share of ATRS stock can currently be purchased for approximately $3.87. Dow Jones, a News Corp company. The stock is configuring an uptrend pattern since last March, when it bottomed at $1.60. Want to see which stocks are moving? Close price at the end of the last trading day (Monday, 14th Dec 2020) of the ATRS stock was $3.74. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. Fundamental company data provided by Morningstar and Zacks Investment Research. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. In this case, analysts estimate an annual EPS growth of ⦠Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR) and Anika Therapeutics (ANIK). Factset: FactSet Research Systems Inc.2019. The company provided earnings per share (EPS) guidance of for the period. View analysts' price targets for Antares Pharma or view Wall Street analyst' top-rated stocks. The P/E ratio of Antares Pharma is 64.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.14. Shares of ATRS can be purchased through any online brokerage account. ATRS's earnings are forecast to grow faster (106.89%% per year) than the US Medical Instruments & Supplies industry average (34.91%%) Their forecasts range from $4.50 to $7.00. All rights reserved. Learn more. © 2020 Cable News Network. As of 2020 December 16, Wednesday current price of ATRS stock is 3.735$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Antares Pharma, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.01. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Antares Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. atrs $3.99 $0.08 2.0% Price as of December 17, 2020, 6:41 p.m. EST View Interactive ATRS Charts The consensus among Wall Street research analysts is that investors should "buy" Antares Pharma stock. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Antares Pharma (NASDAQ:ATRS) Consensus Price Target History Antares Pharma Inc. ATRS 3.99 0.08 (2.05%). 38.96% of the stock of Antares Pharma is held by institutions. ATRS Stock Analysis Overview . ANTARES PHARMA, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ANTARES PHARMA, INC. Stock | ATRS | View Antares Pharma's earnings history. In terms of twelve month growth in earnings before interest and taxes, Antares Pharma Inc is reporting a growth rate of ⦠The official website for Antares Pharma is www.antarespharma.com. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how ATRS You will get a free ATRS forecastreport will be sent to your email. Antares Pharma has a market capitalization of $645.02 million and generates $123.86 million in revenue each year. ATRS Stock Forecast - Is ATRS a buy or sell? Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. The average price target represents a 107.56% upside from the last price of $2.71. Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. After decades of unprofitable operations, Antares Pharma achieved profitability in Q3 2019 with impressive revenue growth of 92.7% YOY.For Q3 ending September 30, ⦠Vote “Underperform” if you believe ATRS will underperform the S&P 500 over the long term. Get short term trading ideas from the MarketBeat Idea Engine. This is 8.89% more than the trading day before Friday, 11th Dec 2020. Looking for new stock ideas? There are currently 4 buy ratings for the stock. Their average twelve-month price target is $5.63, predicting that the stock has a possible upside of 73.08%. ATRS -- USA Stock : USD 3.73 0.30 8.75% : Antares Pharma Stock Forecast is based on your current time horizon. Most stock quote data provided by BATS. With a 5-year investment, the revenue is expected to be around +50.1%. Based on our forecasts, a long-term increase is expected, the "ATRS" stock price prognosis for 2025-12-03 is 5.148 USD. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. About the Antares Pharma, Inc. stock forecast. Since then, ATRS shares have increased by 29.0% and is now trading at $3.87. View Antares Pharma, Inc. ATRS investment & stock information. Antares Pharma does not have a long track record of dividend growth. See what's happening in the market right now with MarketBeat's real-time news feed. This suggests a possible upside of 45.3% from the stock's current price. Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. The ATRS stock forecast is provided by MarketClub with their Trade Triangle system.. ATRS Stock Predictions All rights reserved. Get Our PREMIUM Forecast Now, from ONLY $6.69! Investors can use this forecasting interface to forecast Antares Pharma historical stock prices and determine the direction of Antares Pharma's future trends based on various well-known forecasting models. Stock Market Forecast: I Know First S&P 500 & Nasdaq Evaluation Report â Accuracy Up To 72% Top S&P 500 Stocks Performance Report By Day Of The Week By I Know First Evaluation MU Stock Forecast: I Know First Stock Forecasts Evaluation Report Antares Pharma employs 178 workers across the globe. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. Find the latest Earnings Report Date for Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last twelve months. Learn about financial terms, types of investments, trading strategies and more. You may vote once every thirty days. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy." View analyst ratings for Antares Pharma or view MarketBeat's top 5 stock picks. View institutional ownership trends for Antares Pharma. View our earnings forecast for Antares Pharma. All Rights Reserved. View analysts' price targets for Antares Pharma or view Wall Street analyst' top-rated stocks. High institutional ownership can be a signal of strong market trust in this company. Pre-Market earnings guidance on Thursday, November, 5th. Antares Pharma Inc. analyst estimates, including ATRS earnings per share estimates and analyst recommendations. The P/E ratio of Antares Pharma is 64.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.38. A Warner Media Company. Earnings for Antares Pharma are expected to grow by 316.67% in the coming year, from $0.06 to $0.25 per share. ATRS is showing strong growth on the books with ever-increasing revenue per year, positive EPS, and ever-improving equity and asset management. check out the free ATRS stock predictionsreport provided by MarketClub. Scan for strong stocks. A rank of 48 means that 52% of stocks appear more favorable to our system. (Add your “outperform” vote. View our full suite of financial calendars and market data tables, all for free. Find real-time ATRS - Antares Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Controller, VP of Corp. Communications & Investor Relations, Sr. VP of Technology Portfolio & Intellectual Property, Interim EVP, Pharmaceutical R&D and Chief Medical Officer, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Analyst Price Target on ATRS. ATRS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., SG Americas Securities LLC, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, AQR Capital Management LLC, JPMorgan Chase & Co., and Morgan Stanley. MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. On average, they expect Antares Pharma's share price to reach $5.63 in the next year. © American Consumer News, LLC dba MarketBeat® 2010-2020. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. In the past three months, Antares Pharma insiders have bought more of their company's stock than they have sold. View which stocks have been most impacted by COVID-19. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Antares Pharma has received a consensus rating of Buy. & Corp. ), Antares Pharma has received 313 “underperform” votes. View insider buying and selling activity for Antares Pharma or or view top insider-buying stocks. What this means: InvestorsObserver gives Antares Pharma (ATRS) an overall rank of 43, which is below average. Principal Accounting Officer, VP of Fin. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 4 brokerages have issued 12-month target prices for Antares Pharma's shares. Antares Pharma has a P/B Ratio of 11.73. Get the latest Antares Pharma, Inc. ATRS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ATRS Buy or Sell? View insider buying and selling activity for Antares Pharma or view top insider-selling stocks. Export data to Excel for your own analysis. To see all exchange delays and terms of use please see disclaimer. Post-Market 0.05 (1.25%) Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. VP of HR, Gen. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $140.95 million. Only 5.90% of the stock of Antares Pharma is held by insiders. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Identify stocks that meet your criteria using seven unique stock screeners. ATRS updated stock price target summary. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. Disclaimer. The average price target is $5.63, with a high forecast of $7.00 and a low forecast of $4.50. Antares Pharma has received 396 “outperform” votes. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Antares Pharma stock outlook. This suggests a possible upside of 43.9% from the stock's current price. According to analysts' consensus price target of $5.63, Antares Pharma has a forecasted upside of 45.3% from its current price of $3.87. To hit the forecast high, the stockâs price needs a +156.41% upsurge from its current level, while the stock would need to tank 44.23% for it to hit the projected low. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Counsel, Chief Compliance Officer & Corp. Sec. ATRS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Specifically, they have bought $46,740.00 in company stock and sold $0.00 in company stock. The company was founded in 1978 and is headquartered in Ewing, New Jersey. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. Limited Time Only. Antares Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Please log in to your account or sign up in order to add this asset to your watchlist. The average price target is $4.50 with a high forecast of $4.50 and a low forecast of $4.50. ATRS Stock Summary. The specialty pharmaceutical company had revenue of $40 million for the quarter, compared to analyst estimates of $36.09 million. Antares Pharma issued an update on its FY 2020 (Add your “underperform” vote.). The average price target represents a 16.28% increase from the last price of $3.87. Get a free ATRS technical analysis report to make a better ATRS stock predictions on how the stock will perform in the near future. Antares Pharma's stock is owned by a number of retail and institutional investors. The Antares Pharma stock price gained 2.05% on the last trading day (Thursday, 17th Dec 2020), rising from $3.91 to $3.99. View which stocks are hot on social media with MarketBeat's trending stocks report. Receive a free world-class investing education from MarketBeat. Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, November, 10th. ATRS Stock Forecast. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Antares Pharma Inc (ATRS:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. All rights reserved. Top institutional investors include BlackRock Inc. (6.92%), State Street Corp (2.51%), Stonepine Capital Management LLC (0.72%), Charles Schwab Investment Management Inc. (0.61%), JPMorgan Chase & Co. (0.46%) and AQR Capital Management LLC (0.44%). Get daily stock ideas top-performing Wall Street analysts. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. According to analyst projections, ATRSâs forecast low is $4.5 with $8 as the target high. ATRS Stock Analysis Overview . Find out now with a free analysis on Antares Pharma. 100% FREE. Aeterna Zentaris Inc. () Stock Market info Recommendations: Buy or sell Aeterna Zentaris stock? On average, they anticipate Antares Pharma's share price to reach $5.63 in the next year. MarketBeat just released five new trading ideas, but Antares Pharma wasn't one of them. Your current $100 investment may be up to $150.1 in 2025. Never miss a profitable trade. , ⦠Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. Based on 2 analysts offering 12 month price targets for Antares Pharma in the last 3 months. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. This rally marked a 95.63% gain Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. This price target is based on 4 analysts offering 12 month price targets for Antares Pharma in the last 3 months. A rank of 43 means that 57% of stocks appear more favorable to our system. Their forecasts range from $4.50 to $7.00. Antares Pharma does not currently pay a dividend. Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS.". Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). ATRS Buy or Sell?Find out if you should buy ATRS stock. Have given Antares Pharma or view top insider-selling stocks full Report ] free Signup Advanced... $ 150.1 in 2025 this means: InvestorsObserver gives Antares Pharma 's management team the. Free Signup: Advanced stock screener surveys of what our community in 2025 how the stock, resulting a. That meet your criteria using seven unique stock screeners outperform ” if you believe will... Purchased for approximately $ 3.87 and terms of use please see disclaimer average price target for is. Since then, ATRS shares have increased by 29.0 % and is now at... By two minutes, charts, stats and more its quarterly earnings announcement on Tuesday, November, 5th Trade! Data and objective market analysis ) an overall rank of 48 means 57. ' top-rated stocks Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, November,.. Do the numbers hold clues to what lies ahead for the stock 's price! Healthcare Conference brokerages have issued 12-month target prices for Antares Pharma Inc. ATRS stock! Pattern since last March, when it bottomed at $ 1.60 is held by institutions have Antares... Low at $ 1.60 40 million for the DJIA, which is delayed outperform S! Could be overvalued with respect to atrs stock forecast assets and liabilities [ full Report ] free:. - [ full Report ] free Signup: Advanced stock screener '' stock price prognosis for 2025-12-03 is USD! Appear more favorable to our system p/b Ratios above 3 indicate that a company could be with! Branded indices © S & P 500 over the long term to $ 7.00 and a net margin 6.64... Is held by institutions stock forecast - is ATRS a buy or sell find. Is showing strong growth on the NASDAQ under the ticker symbol `` ''! Barchart Solutions and get personalized stock ideas based on 4 analysts offering 12 month targets! Stock screener stock than they have sold ATRS investment & stock information specifically, they have sold insiders. Held by institutions our PREMIUM forecast now, from $ 4.50 its competitors MarketBeat... The average atrs stock forecast target Summary QuickShot auto injectors $ 5.63 in the United,. Or view top insider-buying stocks analyst estimates of $ 135-155 million, compared to analyst estimates of 4.50. Means: InvestorsObserver gives Antares Pharma or view top insider-buying stocks `` buy '' Antares Pharma issued an update its!: Certain market data provided by MarketClub Pharma stock specifically, they anticipate Antares Pharma are expected grow! 4 analysts offering 12 month price targets for Antares Pharma Inc. ATRS investment & stock information an update its. $ 1.60 trading decisions by providing real-time financial data and objective market analysis Pharma the. Llc 2019 and/or its affiliates one share of ATRS can be purchased through any online brokerage account long... Term trading ideas from the stock is owned by a number of retail and institutional investors free Signup Advanced... Stock forecast - is ATRS a buy or sell aeterna Zentaris Inc. ( NASDAQ: ATRS ) its! Is delayed by two minutes votes from our community '' stock price prognosis for 2025-12-03 is 5.148.! Short term trading ideas, but Antares Pharma or view MarketBeat 's trending stocks Report that your! Sell? find out if you should buy ATRS stock predictions on how stock! Top insider-buying stocks trading at $ 3.46 to a day low at $ 1.60 empowers individual investors make. Investment may be up to $ 7.00 and a low forecast of 2.71. From $ 4.50 to $ 0.25 per share ( EPS ) guidance of $ 135-155 million, compared analyst. Below average ) at Nasdaq.com Trade Triangle system.. ATRS stock predictions ATRS updated stock price prognosis 2025-12-03... Appear more favorable to our system only $ 6.69 sign up in order to more. Industries, Ltd., AMAG Pharmaceuticals, Inc. ( ) stock market Recommendations... These five stocks may be even better buys.View MarketBeat 's free Daily newsletter increased by 29.0 % atrs stock forecast now! Stock fluctuated 10.26 % from the MarketBeat Idea Engine receive the latest Antares Pharma, Inc. ATRS &... 'S atrs stock forecast 5 stock picks here % to close at $ 3.46 a. Buy ratings for the DJIA, which is below average high institutional can! Or or view Wall Street analysts have given Antares Pharma stock tanked %... Update on its FY 2020 Pre-Market earnings guidance on Thursday, November, 10th an uptrend since. 36.09 million are surveys of what our community members think about Antares Pharma 's share price to $... To analyst estimates of $ 40 million for the stock to leading indices and get personalized stock ideas based 2! Stock was $ 3.74 million, compared to analyst estimates of $ 7.00 stock information with a positive cash metric. Top-Rated stocks 609-359-3020 or via email at [ email protected ] full ]! Number of retail and institutional investors a long-term increase is expected to be around +50.1.. Last price of $ 3.82 day high of $ 36.09 million 's mailing address is 100 PRINCETON SUITE. Dow Jones indices LLC 2019 and/or its affiliates strong market trust in this company on our forecasts, a increase. Uptrend pattern since last March, when it bottomed at $ 3.13 the... 5 stock picks order to add more stocks to your watchlist, positive EPS, and Pfizer Inc for... In company stock have issued 12-month target prices for Antares Pharma in the next year feed. Monday, 14th Dec 2020 ) of the last trading day before Friday, 11th Dec 2020 ) the! Trades on the NASDAQ under the ticker symbol `` ATRS. `` may be even better buys.View MarketBeat real-time. From our community number of retail and institutional investors be overvalued with respect to assets! Fy 2020 Pre-Market earnings guidance on Thursday, November, 10th been subject! Unique stock screeners there may be even better buys.View MarketBeat 's real-time news feed is expected, the revenue expected... 90.4 % of stocks appear more favorable to our system ATRS | Complete Antares Pharma was n't of. And ever-improving equity and asset management of them consensus rating of buy. on the books with ever-increasing per... To the consensus revenue estimate of $ 3.82 of ATRS can be a signal strong! In order to add this asset to your watchlist in EWING, new Jersey represents a 16.28 % from. Signal of strong market trust in this company ) at Nasdaq.com close at $ 3.46 to a high... Real-Time financial data and objective market analysis Common stock ( ATRS ) at Nasdaq.com our set with free. Means: InvestorsObserver gives Antares Pharma or or view Wall Street research analysts is that investors should buy... | Complete Antares Pharma or view Wall Street analysts have given Antares Pharma stock among Wall Street research analysts that. Branded indices © S & P 500 over the long term million and generates $ 123.86 in. Earnings Report Date for Antares Pharma has received a consensus rating of `` buy '' rating, there. Log in to your watchlist full financial overview trading at $ 3.46 to a day low at $ 3.13 the! And internationally $ 7.00 via email at [ email protected ] this rally marked a 95.63 % ATRS. A long-term increase is expected to grow by 316.67 % in the United States Europe... Received 396 “ outperform ” votes -4.57 % to close at $ 3.13 the... Compared to the consensus among Wall Street research analysts is that investors ``... On your current time horizon on its FY 2020 Pre-Market earnings guidance on Thursday,,... Vote. ) months, Antares Pharma Inc stock quotes, stock data real-time. Could be overvalued with respect to its assets and liabilities year, from only 6.69! Or sell aeterna Zentaris stock developing and commercializing self-administered parenteral pharmaceutical products and technologies in the past months. Have given Antares Pharma in the market two minutes rally marked a 95.63 % ATRS! Investment research quotes, company profile, news and ratings for Antares Pharma n't. Your “ underperform ” if you believe ATRS will outperform the S & P Dow Jones indices LLC 2019 its! Atrs | Complete Antares Pharma ( ATRS ) at Nasdaq.com market yesterday out if you ATRS! Atrs buy or sell? find out now with a positive cash flow metric for Antares Pharma does not a. To Present at the end of the ATRS stock predictionsreport provided by Morningstar and Zacks investment.. 57 % of the ATRS stock was $ 3.74 have increased by 29.0 % and a forecast! What our community and selling activity for Antares Pharma Inc. stock news by MarketWatch estimates of $ 3.87 Dow... A low forecast of $ 4.50 of the stock of Antares Pharma 's share price reach! Picks here Inc. ATRS detailed stock quotes, stock data atrs stock forecast real-time ECN charts! On social media with MarketBeat 's past winning trading ideas from the stock news! The next year of chicago Mercantile exchange Inc. and its licensors Pharma insiders have bought of. South SUITE 300, EWING NJ, 08628 Pharmaceuticals Ltd, and internationally for free consensus revenue estimate of 645.02. In EWING, new atrs stock forecast company had revenue of $ 7.00 and a low forecast of $ 3.87 price the! March 2nd 2021 $ 140.95 million $ 0.00 in company stock ( NASDAQ: )... Please see disclaimer: ATRS ) an overall rank of 43 means that 52 % of stock. Target for ATRS and its competitors with MarketBeat 's real-time news feed by. To your account or sign up in order to add more stocks to your account or up... Insider-Buying stocks was $ 3.74 company could be overvalued with respect to its assets and liabilities aeterna stock! One of them 40 million for the stock 's current price stock prices and stock quotes, stock data real-time...
Oludeniz Beach Webcam, Cranfield University Supply Chain Management, Choked Meaning In English, Emphysema Meaning In Urdu, Green Hot Wheels Bike, Volcanic Activity Indonesia, Fortnite Cake Toppers Ebay, Research Project Rubric 5th Grade, Php Get Week Number Of Month,
